-+ 0.00%
-+ 0.00%
-+ 0.00%
There are so many GLP-1 giants, why can Pidacan still break through health insurance? The differentiated value of Peger Biotech (02565) ushered in the release
Share
Listen to the news

As star drugs such as simeglutide and tirpotide continue to refresh the market's perception of the effects of GLP-1 drugs in lowering sugar and weight loss, and innovative domestic pharmaceutical companies are also stepping up this circuit one after another, there seems to be no shortage of good drugs in the GLP-1 market. However, on the other side of the continued expansion of the market, the phenomenon of some patients discontinuing medication due to gastrointestinal adverse reactions, treatment costs, etc., still exists. For type 2 diabetics who need long-term blood sugar control, drugs not only need to be effective, but also need to balance tolerability, ease of treatment, and affordability of long-term medication. These clinical needs, which have not been fully met, are providing new development space for GLP-1 innovative drugs with differentiated characteristics.

Recently, Peger Biotech (02565) announced that its self-developed national Class 1 innovative drug, vipernatide injection (trade name: Pidacan®), has been successfully included in the 2026 National Medical Insurance Drug List. Against the backdrop of increasingly rich GLP-1 product choices and continued intensification of market competition, Pidacang successfully entered the national medical insurance catalogue, not only adding an innovative treatment option with medical insurance payment support for patients, but also creating favorable conditions for further release of their differentiated clinical value. What is particularly noteworthy is that Pidacan has the characteristics of initial treatment without dose titration. At the same time, it has accumulated clinical research data on long-term sugar control and gastrointestinal tolerance, which is expected to form a recognizable competitive advantage in the huge type 2 diabetes treatment market.

The next competition in the GLP-1 market: from efficacy to long-term treatment experience

In recent years, GLP-1 drugs have become one of the most popular drug categories in the treatment of metabolic diseases worldwide due to their remarkable hypoglycemic and weight loss effects. As many innovative products are launched one after another, clinical treatment options continue to be enriched, and market competition gradually extends from simply focusing on efficacy indicators to multiple dimensions such as safety, tolerability, convenience of treatment, and long-term patient medication experience. For diabetes, a chronic disease that requires long-term management, it is worth paying attention to whether patients can continue to receive treatment as much as whether drugs can achieve effective blood sugar control.

Real world research supports this need. A 2026 study involving 1,374 GLP-1 users showed that 31.7% of patients stopped treatment within 180 days; among those who stopped taking the drug, 26.8% recorded adverse drug reactions, and 14.4% had cost concerns. Gastrointestinal adverse reactions such as nausea, vomiting, and diarrhea are one of the issues receiving more attention during treatment with GLP-1 drugs. Some patients who are more sensitive to gastrointestinal reactions may face challenges in the continuity of treatment as a result. This means that even if the market already has many GLP-1 products with outstanding curative effects, they still have important clinical significance in response to the differentiated needs of different patients in terms of tolerability, treatment preferences, and financial burden.

Judging from market trends, competition for GLP-1 drugs is not a simple efficacy ranking. There are differences in age, disease progression, physical condition, and drug tolerance among patients, and clinical treatment also needs to take into account individualized needs. For some patients, pursuing stronger sugar reduction or weight loss effects is not the only goal. Being able to effectively control blood sugar while obtaining a better treatment experience and reducing the burden of medication management also has practical value. As the market matures, products that can respond to these specific needs are expected to establish their own market positions among different patient groups.

No dose titration required, Pidacan shows differentiated clinical advantages

Paidacan is a long-acting GLP-1 receptor agonist independently developed by Peger Biotech. It is administered once a week and approved for blood sugar control in adult type 2 diabetics in November 2025. Unlike some GLP-1 products that require starting at a lower dose and gradually increasing to a therapeutic dose, Pidacan has the characteristic of being treated immediately without dose titration. Patients can administer the drug according to the approved plan from the beginning of treatment, reducing the step by step adjustment process. This feature helps simplify the clinical treatment process and also provides more convenient treatment options for patients requiring long-term medication.

In terms of gastrointestinal tolerability, Pidacan's clinical study data are also worth paying attention to. According to public studies, the incidence of nausea, vomiting, bloating, and diarrhea was 8.0%, 5.1%, 5.1%, and 7.3%, respectively, in the vipenatide treatment group, showing attractive gastrointestinal tolerability. At the same time, Paidacan's key clinical study provided 52 weeks of long-term treatment data, showing that the product can achieve continuous and stable blood sugar control. Weekly administration, no dose titration, long-term stable sugar control, and remarkable tolerability data all make up Pidacan's differentiated product characteristics.

This differentiated positioning is of practical significance in the current GLP-1 market. As clinical treatment options continue to increase, doctors can choose different treatment plans according to the patient's specific situation, and for patients who value gastrointestinal tolerance, convenience of treatment, and long-term blood sugar management, Pidacan provides innovative treatment options with different dosage characteristics. The competitiveness of its products does not depend on a single-dimensional comparison with other drugs in all efficacy indicators, but rather responds to the diversified needs of diabetic patients by balancing long-term sugar control, tolerability, and convenience of administration.

Successful entry into medical insurance despite fierce competition, and differentiated clinical value ushered in a wider market

Against the backdrop of competition in the domestic GLP-1 market continuing to heat up, Pidacang was successfully included in the national medical insurance drug catalogue, which is of remarkable industry significance. With the continuous emergence of innovative drugs, the medical insurance payment system not only improves patients' accessibility to medication, but also provides a wider range of application conditions for treatment plans with different clinical characteristics. Pidacang has now been granted medical insurance approval, so that it does not require dose titration, long-term stable sugar control, and gastrointestinal tolerance, and has the opportunity to benefit more type 2 diabetics with actual treatment needs.

It is particularly noteworthy that tolerability and financial burden are important factors affecting long-term treatment for some GLP-1 users. The differentiated characteristics of Paidacan in terms of convenience and tolerability of treatment are expected to mutually promote the effects of improving payment conditions brought about by medical insurance admission. On the one hand, the clinical characteristics of the product itself provide doctors with different treatment options; on the other hand, medical insurance payment support is expected to reduce the long-term medication burden of patients who meet the payment conditions, so that more patients can obtain innovative treatment plans suitable for their own needs. For patients with chronic diseases who use medication for a long time, this combination of clinical value and affordability is of practical significance.

China has a large population of type 2 diabetes patients, and there are differences in the needs of different patients for drug efficacy, safety, tolerability, and ease of treatment. Even in a market where GLP-1 products are increasingly abundant, innovative drugs with clear differentiating characteristics still have market space worth paying attention to. Pidacang has entered the national medical insurance catalogue, creating favorable conditions for it to further expand clinical coverage and serve different patient groups. It is also expected that its product characteristics will be transformed into wider clinical application opportunities.

Medical insurance access resonates with actual clinical needs, and commercialization has ushered in new opportunities

For Peger Biotech, this medical insurance entry was not only an important breakthrough in market entry for core products, but also further improved the commercialization conditions for Peger Biotech. Previously, the company had reached an exclusive commercial cooperation with Shanghai Tengrui Pharmaceutical to promote products in the Chinese market using specialized commercial resources. As Paidacang successfully enters the national health insurance catalogue, the synergy between differentiated clinical characteristics of products, medical insurance payment support, and commercialization promotion systems is expected to gradually become apparent, creating more favorable conditions for hospital access, channel coverage, and clinical prescription growth.

Unlike some short-term drugs, patients with type 2 diabetes usually require long-term blood sugar management, and continuous and standardized treatment requirements provide a long-term market foundation for related innovative drugs. The weekly administration characteristics of Pidacan without dose titration help simplify the treatment process; its long-term sugar control and gastrointestinal tolerance data support clinical application; medical insurance admission is expected to further improve the financial burden of long-term medication use on patients. As these factors gradually form a synergy, Paidacan is expected to accelerate the expansion of medical institution coverage and prescription applications, and drive the growth of product sales scale.

From product approval to launch, to establishment of a commercial cooperation system, to successful inclusion in the national health insurance catalogue, Peger Biotech is continuing to improve the commercialization layout of the first innovative drug. The importance of health insurance admission this time is not only that it has received payment support from the national basic medical insurance system, but also that the differentiated clinical characteristics of Pidacang are more closely linked to the actual treatment needs of a huge patient population. Against the backdrop of increasingly intense competition in the GLP-1 market and continuous segmentation of patients' treatment needs, Pidacan, which has both long-term sugar control effects, treatment convenience, and tolerability, is expected to gradually unleash commercial growth potential with a clearer market positioning.

As health insurance policies are implemented and commercialization continues to advance, Patercon is expected to allow more patients with type 2 diabetes to obtain innovative treatment options and inject new impetus into Peger Biotech's future sales revenue growth. For this innovative pharmaceutical company, which is accelerating commercialization, the first core product successfully entered the national medical insurance catalogue, which is not only an important milestone for innovative research and development results to wider clinical application, but also opens up new space for the company's long-term development in the metabolic disease treatment market in China.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending